Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Revenue (2023 - 2025)

CG Oncology filings provide 3 years of Revenue readings, the most recent being $2.3 million for Q4 2025.

  • On a quarterly basis, Revenue rose 409.21% to $2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 million, a 254.7% increase, with the full-year FY2025 number at $4.0 million, up 254.7% from a year prior.
  • Revenue hit $2.3 million in Q4 2025 for CG Oncology, up from $1.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $2.3 million in Q4 2025 to a low of $1000.0 in Q4 2023.
  • Median Revenue over the past 3 years was $152500.0 (2023), compared with a mean of $538300.0.
  • Biggest five-year swings in Revenue: soared 45500.0% in 2024 and later tumbled 90.17% in 2025.
  • CG Oncology's Revenue stood at $1000.0 in 2023, then soared by 45500.0% to $456000.0 in 2024, then soared by 409.21% to $2.3 million in 2025.
  • The last three reported values for Revenue were $2.3 million (Q4 2025), $1.7 million (Q3 2025), and $52000.0 (Q1 2025) per Business Quant data.